ATE296628T1 - Integrinhemmer zur behandlung von augenkrankheiten - Google Patents

Integrinhemmer zur behandlung von augenkrankheiten

Info

Publication number
ATE296628T1
ATE296628T1 AT02748841T AT02748841T ATE296628T1 AT E296628 T1 ATE296628 T1 AT E296628T1 AT 02748841 T AT02748841 T AT 02748841T AT 02748841 T AT02748841 T AT 02748841T AT E296628 T1 ATE296628 T1 AT E296628T1
Authority
AT
Austria
Prior art keywords
treatment
eye diseases
integrin inhibitors
integrin
inhibitors
Prior art date
Application number
AT02748841T
Other languages
English (en)
Inventor
Hans Markus Bender
Jutta Haunschild
Ulrich Lang
Matthias Wiesner
Martin Friedlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE296628T1 publication Critical patent/ATE296628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
AT02748841T 2001-08-01 2002-07-03 Integrinhemmer zur behandlung von augenkrankheiten ATE296628T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
ATE296628T1 true ATE296628T1 (de) 2005-06-15

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748841T ATE296628T1 (de) 2001-08-01 2002-07-03 Integrinhemmer zur behandlung von augenkrankheiten

Country Status (20)

Country Link
US (2) US20040198644A1 (de)
EP (1) EP1411926B1 (de)
JP (1) JP2005504757A (de)
KR (1) KR20040028966A (de)
CN (1) CN1536998A (de)
AR (1) AR036199A1 (de)
AT (1) ATE296628T1 (de)
AU (1) AU2002319282B2 (de)
BR (1) BR0211604A (de)
CA (1) CA2456076C (de)
DE (1) DE60204466T2 (de)
DK (1) DK1411926T3 (de)
ES (1) ES2243744T3 (de)
HU (1) HUP0401605A3 (de)
MX (1) MXPA04000839A (de)
PL (1) PL207175B1 (de)
PT (1) PT1411926E (de)
RU (1) RU2311177C2 (de)
WO (1) WO2003013511A1 (de)
ZA (1) ZA200401598B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
JP4598399B2 (ja) 2002-02-04 2010-12-15 エラン ファーマ インターナショナル，リミティド 表面安定剤としてリゾチームを有するナノ粒子組成物
AR056320A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
JP5359879B2 (ja) 2007-11-16 2013-12-04 宇部興産株式会社 ベンズアゼピノン化合物
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
EP2538929A4 (de) 2010-02-25 2014-07-09 Univ Johns Hopkins Verzögerte freisetzung von therapiemitteln in einen teil des auges
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CA3007198A1 (en) * 2015-12-04 2017-06-08 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
JP7213804B2 (ja) * 2016-11-08 2023-01-27 ブリストル－マイヤーズ スクイブ カンパニー αＶインテグリンアンタゴニストとしてのインダゾール誘導体
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1313146C (zh) * 1995-08-14 2007-05-02 斯克里普斯研究学院 用于抑制αvβ5介导的血管生成的方法和组合物
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
PT951295E (pt) * 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
WO1997045137A1 (en) * 1996-05-31 1997-12-04 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
WO1999045909A2 (en) * 1998-03-13 1999-09-16 Centaur Pharmaceuticals Use of nitrone compounds for the inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
CA2456076A1 (en) 2003-02-20
RU2004106527A (ru) 2005-07-10
JP2005504757A (ja) 2005-02-17
US20040198644A1 (en) 2004-10-07
AU2002319282B2 (en) 2007-06-28
AR036199A1 (es) 2004-08-18
PL207175B1 (pl) 2010-11-30
HUP0401605A2 (hu) 2004-11-29
KR20040028966A (ko) 2004-04-03
PT1411926E (pt) 2005-10-31
DE60204466D1 (de) 2005-07-07
WO2003013511A1 (en) 2003-02-20
MXPA04000839A (es) 2004-05-14
BR0211604A (pt) 2004-08-24
ES2243744T3 (es) 2005-12-01
CN1536998A (zh) 2004-10-13
ZA200401598B (en) 2004-11-17
HUP0401605A3 (en) 2012-09-28
PL367959A1 (en) 2005-03-07
US20060287225A1 (en) 2006-12-21
US7645736B2 (en) 2010-01-12
EP1411926A1 (de) 2004-04-28
DE60204466T2 (de) 2006-04-27
EP1411926B1 (de) 2005-06-01
CA2456076C (en) 2011-08-23
DK1411926T3 (da) 2005-08-29
RU2311177C2 (ru) 2007-11-27

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411926

Country of ref document: EP